JP2016520635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520635A5 JP2016520635A5 JP2016517273A JP2016517273A JP2016520635A5 JP 2016520635 A5 JP2016520635 A5 JP 2016520635A5 JP 2016517273 A JP2016517273 A JP 2016517273A JP 2016517273 A JP2016517273 A JP 2016517273A JP 2016520635 A5 JP2016520635 A5 JP 2016520635A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- group
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 125000001153 fluoro group Chemical group F* 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- QEAKWTNGOFCWKS-UHFFFAOYSA-N 1-[3-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-5-(2-phenylazetidin-1-yl)-1,2,4-triazol-1-yl]-2-methylpropan-2-ol Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=NN1CC(C)(C)O)N=C1N1CCC1C1=CC=CC=C1 QEAKWTNGOFCWKS-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- CYAPJDDUDHHFKU-UHFFFAOYSA-N 1-[3-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-5-(3-phenylazetidin-1-yl)-1,2,4-triazol-1-yl]-2-methylpropan-2-ol Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=NN1CC(C)(C)O)N=C1N(C1)CC1C1=CC=CC=C1 CYAPJDDUDHHFKU-UHFFFAOYSA-N 0.000 claims 1
- XJCFTIMLWQEHCJ-UHFFFAOYSA-N 1-[5-(1-azaspiro[3.4]octan-1-yl)-3-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-1,2,4-triazol-1-yl]-2-methylpropan-2-ol Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=NN1CC(C)(C)O)N=C1N1CCC11CCCC1 XJCFTIMLWQEHCJ-UHFFFAOYSA-N 0.000 claims 1
- QUCCXLZXXOVQOO-UHFFFAOYSA-N 1-[5-(2-azaspiro[3.3]heptan-2-yl)-3-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-1,2,4-triazol-1-yl]-2-methylpropan-2-ol Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=NN1CC(C)(C)O)N=C1N(C1)CC21CCC2 QUCCXLZXXOVQOO-UHFFFAOYSA-N 0.000 claims 1
- XJLKEFDEVNJFPX-UHFFFAOYSA-N 1-[5-(3-fluoro-3-phenylazetidin-1-yl)-3-[3-methoxy-4-(4-methylimidazol-1-yl)anilino]-1,2,4-triazol-1-yl]-2-methylpropan-2-ol Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=NN1CC(C)(C)O)N=C1N(C1)CC1(F)C1=CC=CC=C1 XJLKEFDEVNJFPX-UHFFFAOYSA-N 0.000 claims 1
- -1 4-methyl-1H-imidazol-1-yl Chemical group 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 229940127236 atypical antipsychotics Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 239000002475 cognitive enhancer Substances 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 239000003695 memory enhancer Substances 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- GYLCFFFLNGLAGA-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-5-(2-phenylazetidin-1-yl)-1,2,4-triazol-3-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=NN1C)N=C1N1CCC1C1=CC=CC=C1 GYLCFFFLNGLAGA-UHFFFAOYSA-N 0.000 claims 1
- OEUYHQOSMXZHIV-UHFFFAOYSA-N n-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-1-methyl-5-(3-phenylazetidin-1-yl)-1,2,4-triazol-3-amine Chemical compound C=1C=C(N2C=C(C)N=C2)C(OC)=CC=1NC(=NN1C)N=C1N(C1)CC1C1=CC=CC=C1 OEUYHQOSMXZHIV-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000001725 pyrenyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1350683 | 2013-06-04 | ||
| SE1350683-7 | 2013-06-04 | ||
| PCT/EP2014/061498 WO2014195321A1 (en) | 2013-06-04 | 2014-06-03 | Triazole compounds and their use as gamma secretase modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520635A JP2016520635A (ja) | 2016-07-14 |
| JP2016520635A5 true JP2016520635A5 (enExample) | 2017-06-01 |
| JP6368776B2 JP6368776B2 (ja) | 2018-08-01 |
Family
ID=50884402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517273A Expired - Fee Related JP6368776B2 (ja) | 2013-06-04 | 2014-06-03 | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9611254B2 (enExample) |
| EP (1) | EP3004081B1 (enExample) |
| JP (1) | JP6368776B2 (enExample) |
| CN (1) | CN105308037B (enExample) |
| WO (1) | WO2014195321A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3212641T (lt) | 2014-10-30 | 2019-02-11 | Janssen Pharmaceutica Nv | Tiazolai, kaip roryt moduliatoriai |
| TWI667230B (zh) | 2014-10-30 | 2019-08-01 | 比利時商健生藥品公司 | 用作ＲＯＲγｔ調節劑之三氟甲基醇 |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| CA3103929A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of roryt |
| EP3806958B1 (en) | 2018-06-18 | 2022-09-07 | Janssen Pharmaceutica NV | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
| ES2925473T3 (es) | 2018-06-18 | 2022-10-18 | Janssen Pharmaceutica Nv | Pirazoles de piridinilo como moduladores de RORyt |
| CN112334450A (zh) | 2018-06-18 | 2021-02-05 | 詹森药业有限公司 | 作为RORγt的调节剂的苯基和吡啶基取代的咪唑 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20030312A1 (it) | 2003-02-21 | 2004-08-22 | Chiesi Farma Spa | Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer. |
| DE602004026597D1 (de) | 2003-08-07 | 2010-05-27 | Merck Sharp & Dohme | Behandlung von alzheimer-krankheit und verwandten zuständen |
| WO2005054193A1 (en) | 2003-12-03 | 2005-06-16 | Merck & Co. Inc. | 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for alzheimer's disease and related conditions |
| BRPI0511504A (pt) | 2004-05-26 | 2008-01-22 | Eisai R&D Man Co Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides |
| CA2649996A1 (en) | 2006-04-26 | 2007-11-08 | Merck Sharp & Dohme Limited | Piperidines and related compounds for treatment of alzheimer's disease |
| JPWO2007135969A1 (ja) | 2006-05-19 | 2009-10-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア系−シンナミド誘導体 |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| JP2010518080A (ja) | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療薬 |
| US8252803B2 (en) | 2007-02-12 | 2012-08-28 | Merck Sharp & Dohme Corp. | Piperidine derivatives |
| EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2008156580A1 (en) * | 2007-06-13 | 2008-12-24 | Merck & Co., Inc. | Triazole derivatives for treating alzheimer's disease and related conditions |
| US20110009392A1 (en) | 2007-08-06 | 2011-01-13 | Schering Corporation | Gamma secretase modulators |
| KR101244517B1 (ko) | 2008-01-11 | 2013-03-18 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타에 대한 조절제 |
| AU2009216851B2 (en) | 2008-02-22 | 2013-11-07 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| US8642583B2 (en) * | 2008-10-30 | 2014-02-04 | Janssen Pharmaceutica Nv | Serotonin receptor modulators |
| MX2011004680A (es) | 2008-11-06 | 2011-05-25 | Astrazeneca Ab | Moduladores de beta amiloide. |
| AU2009312856A1 (en) | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| US8501946B2 (en) * | 2009-04-29 | 2013-08-06 | Glaxo Group Limited | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators |
| UY32622A (es) | 2009-05-12 | 2010-12-31 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) |
| BR112012000915A2 (pt) | 2009-07-15 | 2019-09-24 | Janssen Pharmaceuticals Inc | derivados de triazol e imidazol substituídos como moduladores de gama secretase. |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| AU2011206635B2 (en) | 2010-01-15 | 2015-01-22 | Cellzome Limited | Novel substituted triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| TW201206946A (en) | 2010-07-15 | 2012-02-16 | Bristol Myers Squibb Co | Compounds for the reduction of beta-amyloid production |
| AU2012230348A1 (en) * | 2011-03-24 | 2013-08-29 | Cellzome Limited | Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators |
-
2014
- 2014-06-03 US US14/895,512 patent/US9611254B2/en not_active Expired - Fee Related
- 2014-06-03 WO PCT/EP2014/061498 patent/WO2014195321A1/en not_active Ceased
- 2014-06-03 EP EP14727827.9A patent/EP3004081B1/en not_active Not-in-force
- 2014-06-03 JP JP2016517273A patent/JP6368776B2/ja not_active Expired - Fee Related
- 2014-06-03 CN CN201480031612.5A patent/CN105308037B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513894A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| IL263511A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| JP2017502940A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| WO2013080120A1 (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | |
| JP2017504611A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| MY198769A (en) | Substituted heterocyclic derivatives as cdk inhibitors | |
| JP2018519323A5 (enExample) | ||
| JP2015501799A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2019512535A5 (enExample) | ||
| JP2009510043A5 (enExample) | ||
| CA2648157A1 (en) | 1-alkyl-5-aryl-3-arylamino-1h-1,2,4-triazoles as positive allosteric modulators of the alpha 7 receptor | |
| MX2009013272A (es) | Formas amorfas estabilzadas de mesilato de imatinib. | |
| CA2921436C (en) | Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
| JP2011513475A5 (enExample) | ||
| JP2016526576A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| JP2019512533A5 (enExample) | ||
| NZ776354A (en) | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound | |
| US20180251431A1 (en) | 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels | |
| JP2013542267A5 (enExample) |